Yes. Our English-language service line supports biotech, pharma and CRO teams in North America, Europe and Asia-Pacific. Most work sits under NDA, so we publish application notes instead of client names: donor-dependent potency ranking in HER2-directed ADCC, anti-CD47 and anti-CD20 ADCP with M2 macrophages, anti-PD-1-driven MLR, and 30/40 Gy irradiated PBMC feeder cells that stop proliferating and disintegrate on schedule. On a call we can walk you through a comparable anonymized program – assay design, donor selection, turnaround and the documentation that was delivered.
